Sorrento Therapeutics, Inc. to present late breaking positive clinical trial data FOR resiniferatoxin at two prestigious upcoming pain conferences. Phase 1b2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to move to Phase III pivotal studies in second quarter 2020. Phase 1b Cancer Pain completed enrollment of initial cohorts (14 patients) with no dose limiting toxicities observed and efficacy signal confirmed. One expansion cohort (3 to 6 additional patients) was added to allow for better determination of the dosing regimen. The program is expected to move to a registrational study in second half of 2020.